DaVita's (DVA) streak within the healthcare sector is getting plenty of investor attention, after the successful delivery of the company's kidney care program which reportedly saved $200 million. Meanwhile, the firm has backed R1 Therapeutics with a substantial investment, while its healthcare unit has consistently outperformed the stock market, despite some indication of insider selling. Several analysts and investors seem bullish on DaVita, with some suggesting it may be undervalued. Indeed, after a robust Q4 2025 earnings reveal and upward revision of guidance, reevaluation of DVA's value seems in order. The stock has seen a 30-day surge and a solid multi-year performance, further driving positive speculation among investors. However, concerns linger with some analysts about the security of these gains, including those due to buy-back driven earnings and falling volumes. It's important to note, DVA anticipates steady dialysis service demand, which could boost 2026 profits and anticipates strong growth over the long term despite some volatility risks. Stockholders include firms like Aquatic Capital Management and Doma Perpetual Capital Management, providing ample backing for DVA. Regardless of some pullback, DVA may offer value opportunity to shrewd investors.
Davita DVA News Analytics from Wed, 06 Aug 2025 07:00:00 GMT to Sat, 21 Mar 2026 17:14:12 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor -2
